Sitravatinib Targets TYRO3 to Augment the Anti-Tumor Immune Response of PD-1 Blockade in Hepatocellular Carcinoma

0
434
Scientists investigated the anti-tumor efficacy and immunomodulatory activity of sitravatinib in hepatocellular carcinoma.
[Clinical Cancer Research]
Abstract